Loading…
Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Allogeneic hematopoietic cell transplantation (allo-HCT) with reduced intensity conditioning (RIC) is an option for elderly patients with acute lymphoblastic leukemia (ALL). We retrospectively compared results of RIC-allo-HCT from either a matched sibling donor (MSD, n = 209) or matched unrelated d...
Saved in:
| Published in: | Bone marrow transplantation (Basingstoke) 2023-04, Vol.58 (4), p.393-400 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c409t-fe0697b09e3f06ad7ede11a72b303afafcff616558add746a87f0b5b9737eec13 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c409t-fe0697b09e3f06ad7ede11a72b303afafcff616558add746a87f0b5b9737eec13 |
| container_end_page | 400 |
| container_issue | 4 |
| container_start_page | 393 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 58 |
| creator | Giebel, Sebastian Labopin, Myriam Houhou, Mohamed Caillot, Denis Finke, Jürgen Blaise, Didier Fegueux, Nathalie Ethell, Mark Cornelissen, Jan J. Forcade, Edouard Yakoub-Agha, Ibrahim Lussana, Federico Maertens, Johan Bourhis, Jean Henri Jindra, Pavel Gorin, Norbert Claude Nagler, Arnon Mohty, Mohamad |
| description | Allogeneic hematopoietic cell transplantation (allo-HCT) with reduced intensity conditioning (RIC) is an option for elderly patients with acute lymphoblastic leukemia (ALL). We retrospectively compared results of RIC-allo-HCT from either a matched sibling donor (MSD,
n
= 209) or matched unrelated donor (MUD,
n
= 209) with autologous (auto,
n
= 142) HCT for patients aged 55 years or more treated in first complete remission (CR1) between 2000 and 2018. The probabilities of leukemia-free survival (LFS) at 5 years were 34% for RIC-allo-HCT versus 39% for auto-HCT (
p
= 0.11) while overall survival (OS) rates were 42% versus 45% (
p
= 0.23), respectively. The incidence of relapse (RI) and non-relapse mortality (NRM) was 41% versus 51% (
p
= 0.22) and 25% versus 10% (
p
= 0.001), respectively. In a multivariate model, using auto-HCT as reference, the risk of NRM was increased for MSD-HCT (Hazard ratio [HR] = 2.1,
p
= 0.02) and MUD-HCT (HR = 3.08,
p
|
| doi_str_mv | 10.1038/s41409-022-01904-2 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04480300v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2761978275</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-fe0697b09e3f06ad7ede11a72b303afafcff616558add746a87f0b5b9737eec13</originalsourceid><addsrcrecordid>eNp9ksFu1DAQhiMEokvhBTggS1zgkGLHiZ0cl6pQpEUgUcTRmiTj3bROnNpOq7wvD4KzuxTBgdNoxt_8Mxr_SfKS0TNGefnO5yynVUqzLKWsonmaPUpWLJciLbgoHicrmoky5VxUJ8kz768pZXlOi6fJCReCMVrJVfJzPQVr7NZOntyh8zGAiTkO2DVkhz0EO9oOQ8waNIYEB4MfDQwBQmcHoq0j1rToyBgLOARP7ruwI9BMAYmZ-3FnawN-ETA43WDfwRlZDwQGMLPvPNHO9iTskKz3LZsjRH5Yd9MNW_IVXJiJ1XvmYnJ2RBjIN9vEreb9_PfG2jYKtuQzOGfvydXfSz5PnmgwHl8c42ny_cPF1flluvny8dP5epM28Y4h1UhFJWtaIddUQCuxRcZAZjWnHDToRmvBRFGU0LYyF1BKTeuiriSXiA3jp8nbg-4OjBpd14OblYVOXa43aqnRPC8pp_RuYd8c2NHZ2wl9UH3nlwvDgPEzVCYFq2SZySKir_9Br-3k4vkWqipolecyi1R2oBpnvXeoHzZgVC1-UQe_qOgXtfeLWppeHaWnusf2oeW3QSLAD4CPT8MW3Z_Z_5H9Ba8N0Us</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2795094472</pqid></control><display><type>article</type><title>Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation</title><source>LexisNexis - News & Business</source><source>Springer Link</source><creator>Giebel, Sebastian ; Labopin, Myriam ; Houhou, Mohamed ; Caillot, Denis ; Finke, Jürgen ; Blaise, Didier ; Fegueux, Nathalie ; Ethell, Mark ; Cornelissen, Jan J. ; Forcade, Edouard ; Yakoub-Agha, Ibrahim ; Lussana, Federico ; Maertens, Johan ; Bourhis, Jean Henri ; Jindra, Pavel ; Gorin, Norbert Claude ; Nagler, Arnon ; Mohty, Mohamad</creator><creatorcontrib>Giebel, Sebastian ; Labopin, Myriam ; Houhou, Mohamed ; Caillot, Denis ; Finke, Jürgen ; Blaise, Didier ; Fegueux, Nathalie ; Ethell, Mark ; Cornelissen, Jan J. ; Forcade, Edouard ; Yakoub-Agha, Ibrahim ; Lussana, Federico ; Maertens, Johan ; Bourhis, Jean Henri ; Jindra, Pavel ; Gorin, Norbert Claude ; Nagler, Arnon ; Mohty, Mohamad</creatorcontrib><description>Allogeneic hematopoietic cell transplantation (allo-HCT) with reduced intensity conditioning (RIC) is an option for elderly patients with acute lymphoblastic leukemia (ALL). We retrospectively compared results of RIC-allo-HCT from either a matched sibling donor (MSD,
n
= 209) or matched unrelated donor (MUD,
n
= 209) with autologous (auto,
n
= 142) HCT for patients aged 55 years or more treated in first complete remission (CR1) between 2000 and 2018. The probabilities of leukemia-free survival (LFS) at 5 years were 34% for RIC-allo-HCT versus 39% for auto-HCT (
p
= 0.11) while overall survival (OS) rates were 42% versus 45% (
p
= 0.23), respectively. The incidence of relapse (RI) and non-relapse mortality (NRM) was 41% versus 51% (
p
= 0.22) and 25% versus 10% (
p
= 0.001), respectively. In a multivariate model, using auto-HCT as reference, the risk of NRM was increased for MSD-HCT (Hazard ratio [HR] = 2.1,
p
= 0.02) and MUD-HCT (HR = 3.08,
p
< 0.001), which for MUD-HCT translated into a decreased chance of LFS (HR = 1.55,
p
= 0.01) and OS (HR = 1.62,
p
= 0.008). No significant associations were found with respect to the risk of relapse. We conclude that for patients with ALL in CR1, aged above 55 years, auto-HCT may be considered a transplant option alternative to RIC-allo-HCT, although its value requires verification in prospective trials.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/s41409-022-01904-2</identifier><identifier>PMID: 36611097</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/1541/1990/283/2125 ; 692/700/565/2319 ; Acute Disease ; Acute lymphoblastic leukemia ; Aged ; Allografts ; Autografts ; Bone Marrow ; Bone marrow transplantation ; Cell Biology ; Clinical trials ; Graft vs Host Disease - etiology ; Hematology ; Hematopoietic Stem Cell Transplantation - methods ; Hematopoietic stem cells ; Humans ; Internal Medicine ; Leukemia ; Leukemia, Myeloid, Acute - therapy ; Life Sciences ; Lymphatic leukemia ; Medicine ; Medicine & Public Health ; Mud ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy ; Prospective Studies ; Public Health ; Recurrence ; Remission ; Retrospective Studies ; Stem cell transplantation ; Stem Cells ; Survival ; Transplantation ; Transplantation Conditioning - methods ; Transplantation, Homologous - methods ; Transplants & implants</subject><ispartof>Bone marrow transplantation (Basingstoke), 2023-04, Vol.58 (4), p.393-400</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Nature Limited.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-fe0697b09e3f06ad7ede11a72b303afafcff616558add746a87f0b5b9737eec13</citedby><cites>FETCH-LOGICAL-c409t-fe0697b09e3f06ad7ede11a72b303afafcff616558add746a87f0b5b9737eec13</cites><orcidid>0000-0003-4524-8782 ; 0000-0002-7264-808X ; 0000-0002-4827-4401 ; 0000-0002-0763-1265 ; 0000-0003-4514-4748 ; 0000-0002-1799-5927 ; 0000-0002-5684-9447 ; 0000-0002-8873-2868 ; 0000-0002-0108-5769 ; 0000-0002-8415-7069 ; 0000-0002-6510-8616</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36611097$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lille.fr/hal-04480300$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Giebel, Sebastian</creatorcontrib><creatorcontrib>Labopin, Myriam</creatorcontrib><creatorcontrib>Houhou, Mohamed</creatorcontrib><creatorcontrib>Caillot, Denis</creatorcontrib><creatorcontrib>Finke, Jürgen</creatorcontrib><creatorcontrib>Blaise, Didier</creatorcontrib><creatorcontrib>Fegueux, Nathalie</creatorcontrib><creatorcontrib>Ethell, Mark</creatorcontrib><creatorcontrib>Cornelissen, Jan J.</creatorcontrib><creatorcontrib>Forcade, Edouard</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><creatorcontrib>Lussana, Federico</creatorcontrib><creatorcontrib>Maertens, Johan</creatorcontrib><creatorcontrib>Bourhis, Jean Henri</creatorcontrib><creatorcontrib>Jindra, Pavel</creatorcontrib><creatorcontrib>Gorin, Norbert Claude</creatorcontrib><creatorcontrib>Nagler, Arnon</creatorcontrib><creatorcontrib>Mohty, Mohamad</creatorcontrib><title>Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>Allogeneic hematopoietic cell transplantation (allo-HCT) with reduced intensity conditioning (RIC) is an option for elderly patients with acute lymphoblastic leukemia (ALL). We retrospectively compared results of RIC-allo-HCT from either a matched sibling donor (MSD,
n
= 209) or matched unrelated donor (MUD,
n
= 209) with autologous (auto,
n
= 142) HCT for patients aged 55 years or more treated in first complete remission (CR1) between 2000 and 2018. The probabilities of leukemia-free survival (LFS) at 5 years were 34% for RIC-allo-HCT versus 39% for auto-HCT (
p
= 0.11) while overall survival (OS) rates were 42% versus 45% (
p
= 0.23), respectively. The incidence of relapse (RI) and non-relapse mortality (NRM) was 41% versus 51% (
p
= 0.22) and 25% versus 10% (
p
= 0.001), respectively. In a multivariate model, using auto-HCT as reference, the risk of NRM was increased for MSD-HCT (Hazard ratio [HR] = 2.1,
p
= 0.02) and MUD-HCT (HR = 3.08,
p
< 0.001), which for MUD-HCT translated into a decreased chance of LFS (HR = 1.55,
p
= 0.01) and OS (HR = 1.62,
p
= 0.008). No significant associations were found with respect to the risk of relapse. We conclude that for patients with ALL in CR1, aged above 55 years, auto-HCT may be considered a transplant option alternative to RIC-allo-HCT, although its value requires verification in prospective trials.</description><subject>692/699/1541/1990/283/2125</subject><subject>692/700/565/2319</subject><subject>Acute Disease</subject><subject>Acute lymphoblastic leukemia</subject><subject>Aged</subject><subject>Allografts</subject><subject>Autografts</subject><subject>Bone Marrow</subject><subject>Bone marrow transplantation</subject><subject>Cell Biology</subject><subject>Clinical trials</subject><subject>Graft vs Host Disease - etiology</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Life Sciences</subject><subject>Lymphatic leukemia</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mud</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</subject><subject>Prospective Studies</subject><subject>Public Health</subject><subject>Recurrence</subject><subject>Remission</subject><subject>Retrospective Studies</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Survival</subject><subject>Transplantation</subject><subject>Transplantation Conditioning - methods</subject><subject>Transplantation, Homologous - methods</subject><subject>Transplants & implants</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9ksFu1DAQhiMEokvhBTggS1zgkGLHiZ0cl6pQpEUgUcTRmiTj3bROnNpOq7wvD4KzuxTBgdNoxt_8Mxr_SfKS0TNGefnO5yynVUqzLKWsonmaPUpWLJciLbgoHicrmoky5VxUJ8kz768pZXlOi6fJCReCMVrJVfJzPQVr7NZOntyh8zGAiTkO2DVkhz0EO9oOQ8waNIYEB4MfDQwBQmcHoq0j1rToyBgLOARP7ruwI9BMAYmZ-3FnawN-ETA43WDfwRlZDwQGMLPvPNHO9iTskKz3LZsjRH5Yd9MNW_IVXJiJ1XvmYnJ2RBjIN9vEreb9_PfG2jYKtuQzOGfvydXfSz5PnmgwHl8c42ny_cPF1flluvny8dP5epM28Y4h1UhFJWtaIddUQCuxRcZAZjWnHDToRmvBRFGU0LYyF1BKTeuiriSXiA3jp8nbg-4OjBpd14OblYVOXa43aqnRPC8pp_RuYd8c2NHZ2wl9UH3nlwvDgPEzVCYFq2SZySKir_9Br-3k4vkWqipolecyi1R2oBpnvXeoHzZgVC1-UQe_qOgXtfeLWppeHaWnusf2oeW3QSLAD4CPT8MW3Z_Z_5H9Ba8N0Us</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>Giebel, Sebastian</creator><creator>Labopin, Myriam</creator><creator>Houhou, Mohamed</creator><creator>Caillot, Denis</creator><creator>Finke, Jürgen</creator><creator>Blaise, Didier</creator><creator>Fegueux, Nathalie</creator><creator>Ethell, Mark</creator><creator>Cornelissen, Jan J.</creator><creator>Forcade, Edouard</creator><creator>Yakoub-Agha, Ibrahim</creator><creator>Lussana, Federico</creator><creator>Maertens, Johan</creator><creator>Bourhis, Jean Henri</creator><creator>Jindra, Pavel</creator><creator>Gorin, Norbert Claude</creator><creator>Nagler, Arnon</creator><creator>Mohty, Mohamad</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-4524-8782</orcidid><orcidid>https://orcid.org/0000-0002-7264-808X</orcidid><orcidid>https://orcid.org/0000-0002-4827-4401</orcidid><orcidid>https://orcid.org/0000-0002-0763-1265</orcidid><orcidid>https://orcid.org/0000-0003-4514-4748</orcidid><orcidid>https://orcid.org/0000-0002-1799-5927</orcidid><orcidid>https://orcid.org/0000-0002-5684-9447</orcidid><orcidid>https://orcid.org/0000-0002-8873-2868</orcidid><orcidid>https://orcid.org/0000-0002-0108-5769</orcidid><orcidid>https://orcid.org/0000-0002-8415-7069</orcidid><orcidid>https://orcid.org/0000-0002-6510-8616</orcidid></search><sort><creationdate>20230401</creationdate><title>Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation</title><author>Giebel, Sebastian ; Labopin, Myriam ; Houhou, Mohamed ; Caillot, Denis ; Finke, Jürgen ; Blaise, Didier ; Fegueux, Nathalie ; Ethell, Mark ; Cornelissen, Jan J. ; Forcade, Edouard ; Yakoub-Agha, Ibrahim ; Lussana, Federico ; Maertens, Johan ; Bourhis, Jean Henri ; Jindra, Pavel ; Gorin, Norbert Claude ; Nagler, Arnon ; Mohty, Mohamad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-fe0697b09e3f06ad7ede11a72b303afafcff616558add746a87f0b5b9737eec13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>692/699/1541/1990/283/2125</topic><topic>692/700/565/2319</topic><topic>Acute Disease</topic><topic>Acute lymphoblastic leukemia</topic><topic>Aged</topic><topic>Allografts</topic><topic>Autografts</topic><topic>Bone Marrow</topic><topic>Bone marrow transplantation</topic><topic>Cell Biology</topic><topic>Clinical trials</topic><topic>Graft vs Host Disease - etiology</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Life Sciences</topic><topic>Lymphatic leukemia</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mud</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</topic><topic>Prospective Studies</topic><topic>Public Health</topic><topic>Recurrence</topic><topic>Remission</topic><topic>Retrospective Studies</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Survival</topic><topic>Transplantation</topic><topic>Transplantation Conditioning - methods</topic><topic>Transplantation, Homologous - methods</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giebel, Sebastian</creatorcontrib><creatorcontrib>Labopin, Myriam</creatorcontrib><creatorcontrib>Houhou, Mohamed</creatorcontrib><creatorcontrib>Caillot, Denis</creatorcontrib><creatorcontrib>Finke, Jürgen</creatorcontrib><creatorcontrib>Blaise, Didier</creatorcontrib><creatorcontrib>Fegueux, Nathalie</creatorcontrib><creatorcontrib>Ethell, Mark</creatorcontrib><creatorcontrib>Cornelissen, Jan J.</creatorcontrib><creatorcontrib>Forcade, Edouard</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><creatorcontrib>Lussana, Federico</creatorcontrib><creatorcontrib>Maertens, Johan</creatorcontrib><creatorcontrib>Bourhis, Jean Henri</creatorcontrib><creatorcontrib>Jindra, Pavel</creatorcontrib><creatorcontrib>Gorin, Norbert Claude</creatorcontrib><creatorcontrib>Nagler, Arnon</creatorcontrib><creatorcontrib>Mohty, Mohamad</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giebel, Sebastian</au><au>Labopin, Myriam</au><au>Houhou, Mohamed</au><au>Caillot, Denis</au><au>Finke, Jürgen</au><au>Blaise, Didier</au><au>Fegueux, Nathalie</au><au>Ethell, Mark</au><au>Cornelissen, Jan J.</au><au>Forcade, Edouard</au><au>Yakoub-Agha, Ibrahim</au><au>Lussana, Federico</au><au>Maertens, Johan</au><au>Bourhis, Jean Henri</au><au>Jindra, Pavel</au><au>Gorin, Norbert Claude</au><au>Nagler, Arnon</au><au>Mohty, Mohamad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2023-04-01</date><risdate>2023</risdate><volume>58</volume><issue>4</issue><spage>393</spage><epage>400</epage><pages>393-400</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>Allogeneic hematopoietic cell transplantation (allo-HCT) with reduced intensity conditioning (RIC) is an option for elderly patients with acute lymphoblastic leukemia (ALL). We retrospectively compared results of RIC-allo-HCT from either a matched sibling donor (MSD,
n
= 209) or matched unrelated donor (MUD,
n
= 209) with autologous (auto,
n
= 142) HCT for patients aged 55 years or more treated in first complete remission (CR1) between 2000 and 2018. The probabilities of leukemia-free survival (LFS) at 5 years were 34% for RIC-allo-HCT versus 39% for auto-HCT (
p
= 0.11) while overall survival (OS) rates were 42% versus 45% (
p
= 0.23), respectively. The incidence of relapse (RI) and non-relapse mortality (NRM) was 41% versus 51% (
p
= 0.22) and 25% versus 10% (
p
= 0.001), respectively. In a multivariate model, using auto-HCT as reference, the risk of NRM was increased for MSD-HCT (Hazard ratio [HR] = 2.1,
p
= 0.02) and MUD-HCT (HR = 3.08,
p
< 0.001), which for MUD-HCT translated into a decreased chance of LFS (HR = 1.55,
p
= 0.01) and OS (HR = 1.62,
p
= 0.008). No significant associations were found with respect to the risk of relapse. We conclude that for patients with ALL in CR1, aged above 55 years, auto-HCT may be considered a transplant option alternative to RIC-allo-HCT, although its value requires verification in prospective trials.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>36611097</pmid><doi>10.1038/s41409-022-01904-2</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-4524-8782</orcidid><orcidid>https://orcid.org/0000-0002-7264-808X</orcidid><orcidid>https://orcid.org/0000-0002-4827-4401</orcidid><orcidid>https://orcid.org/0000-0002-0763-1265</orcidid><orcidid>https://orcid.org/0000-0003-4514-4748</orcidid><orcidid>https://orcid.org/0000-0002-1799-5927</orcidid><orcidid>https://orcid.org/0000-0002-5684-9447</orcidid><orcidid>https://orcid.org/0000-0002-8873-2868</orcidid><orcidid>https://orcid.org/0000-0002-0108-5769</orcidid><orcidid>https://orcid.org/0000-0002-8415-7069</orcidid><orcidid>https://orcid.org/0000-0002-6510-8616</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2023-04, Vol.58 (4), p.393-400 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04480300v1 |
| source | LexisNexis - News & Business; Springer Link |
| subjects | 692/699/1541/1990/283/2125 692/700/565/2319 Acute Disease Acute lymphoblastic leukemia Aged Allografts Autografts Bone Marrow Bone marrow transplantation Cell Biology Clinical trials Graft vs Host Disease - etiology Hematology Hematopoietic Stem Cell Transplantation - methods Hematopoietic stem cells Humans Internal Medicine Leukemia Leukemia, Myeloid, Acute - therapy Life Sciences Lymphatic leukemia Medicine Medicine & Public Health Mud Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Prospective Studies Public Health Recurrence Remission Retrospective Studies Stem cell transplantation Stem Cells Survival Transplantation Transplantation Conditioning - methods Transplantation, Homologous - methods Transplants & implants |
| title | Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T02%3A00%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autologous%20versus%20allogeneic%20hematopoietic%20cell%20transplantation%20for%20older%20patients%20with%20acute%20lymphoblastic%20leukemia.%20An%20analysis%20from%20the%20Acute%20Leukemia%20Working%20Party%20of%20the%20European%20Society%20for%20Blood%20and%20Marrow%20Transplantation&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Giebel,%20Sebastian&rft.date=2023-04-01&rft.volume=58&rft.issue=4&rft.spage=393&rft.epage=400&rft.pages=393-400&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/s41409-022-01904-2&rft_dat=%3Cproquest_hal_p%3E2761978275%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c409t-fe0697b09e3f06ad7ede11a72b303afafcff616558add746a87f0b5b9737eec13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2795094472&rft_id=info:pmid/36611097&rfr_iscdi=true |